Clinical Trials Logo

Clinical Trial Summary

A phase II, multicenter, open-label, single-arm study to evaluate the efficacy, safety and pharmacokinetics of SC10914 in subjects with gBRCA1/2 mutated advanced ovarian cancer in china.


Clinical Trial Description

A total of 104 subjects with gBRCA1/2 mutated advanced ovarian cancer is planned to be enrolled to observe the efficacy, safety and PK profile of SC10914. The subjects oral administration SC10914 tablets 400mg on an empty stomach, three times a day, for 28 consecutive days as a treatment cycle, until disease progression (PD) or the toxicity was intolerable. PK blood samples are planned to be collected for each enrolled subject on C1D28 visit. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04556539
Study type Interventional
Source Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Contact Liu chunlei
Phone 13911737489
Email liuchunlei@sh-qingfeng.net
Status Recruiting
Phase Phase 2
Start date December 15, 2020
Completion date December 31, 2022

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03611179 - Upfront Treatment With Chemotherapy and Bevacizumab in Advanced Ovarian Cancer Phase 2
Not yet recruiting NCT06055348 - SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer Phase 1/Phase 2
Completed NCT04135521 - Dose-dense Chemotherapy Versus Intraperitoneal Chemotherapy as First-line Chemotherapy in Advanced Ovarian Cancer
Completed NCT01462149 - Efficacy Study of Neoadjuvant Chemotherapy to Treat Advanced Ovarian Cancer Phase 2
Terminated NCT03292172 - A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer Phase 1
Not yet recruiting NCT05794659 - Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer Phase 2
Completed NCT04360629 - Efficacy and Safety of Tranexamic Acid in Cytoreductive Surgery for Ovarian Cancer N/A
Completed NCT00516724 - Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel Phase 1
Completed NCT03158935 - The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial Phase 1
Completed NCT05775549 - A Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian Cancer
Active, not recruiting NCT03737643 - Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients Phase 3
Completed NCT01290471 - Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors Phase 1
Recruiting NCT04862325 - SOPHIE Trial: Surgery in Ovarian Cancer With PreHabilitation In ERAS N/A
Completed NCT01989546 - Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations Phase 1/Phase 2
Completed NCT03161132 - Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin Phase 2
Active, not recruiting NCT04065009 - The IPLA-OVCA Trial, Intra-Peritoneal Local Anaesthetics in Ovarian Cancer Phase 3
Active, not recruiting NCT01844986 - Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. Phase 3
Not yet recruiting NCT05924776 - Plasmodium Immunotherapy for Advanced Ovarian Cancer Phase 2/Phase 3
Active, not recruiting NCT03878849 - Investigation of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP® Phase 2